- Home
- AOMR vs OBIO Comparison
AOMR vs OBIO Comparison
Compare AOMR & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AOMR | OBIO |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.3M | 237.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | AOMR | OBIO |
|---|---|---|
| Price | $8.80 | $4.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $11.13 | ★ $14.00 |
| AVG Volume (30 Days) | 131.8K | ★ 299.6K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 14.32% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $34,705,000.00 | $2,818,000.00 |
| Revenue This Year | N/A | $36.43 |
| Revenue Next Year | $16.56 | $2.56 |
| P/E Ratio | $12.19 | ★ N/A |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $7.36 | $2.20 |
| 52 Week High | $10.88 | $6.30 |
Technical Indicators
Market Signals| Indicator | AOMR | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 49.97 | 48.09 |
| Support Level | $8.67 | $4.19 |
| Resistance Level | $8.98 | $4.69 |
| Average True Range (ATR) | 0.15 | 0.31 |
| MACD | 0.04 | -0.09 |
| Stochastic Oscillator | 75.39 | 10.53 |
Price Performance
Historical ComparisonAbout AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.